Empagliflozin, nevertheless, improved extra endpoints: it increased urinary result up to time?4 of hospitalisation and reduced a?combined endpoint of in-hospital worsening HF, rehospitalisation for HF or death at 60?times after enrolment in comparison to placebo (4 (10%) vs
Empagliflozin, nevertheless, improved extra endpoints: it increased urinary result up to time?4 of hospitalisation and reduced a?combined endpoint of in-hospital worsening HF, rehospitalisation for HF or death at 60?times after enrolment in comparison to placebo (4 (10%) vs. also assess outcomes of bigger clinical trials which have been executed in holland. HF. The DAPA-HF (Dapagliflozin…